­­

 


Preclinical Studies Using Brain Xenocraft Tumor Models

Atraumatic access to brain tumor models through advanced cOFM technology.
Real-time tumor microenvironment monitoring with intact BBB – accelerating oncology drug development.

 

 

 

 

Our innovative orthotopic xenograft platform enables atraumatic access to brain tumors through cerebral Open Flow Microperfusion (cOFM) technology. We specialize in developing clinically relevant tumor models that maintain intact blood-brain barrier function while providing direct access to the tumor microenvironment for drug development and biomarker research.

We establish orthotopic xenografts through precise implantation of tumor cells directly into brain tissue via cOFM probes, which also remain in place after implantation of tumor cells. We thereby create functional tumor models that closely resemble human pathology. Our unique cOFM-based approach allows for continuous, real-time monitoring of the tumor microenvironment without causing tissue trauma that could compromise data reliability.

 

Our Key Services Include:

  • Atraumatic Tumor Access: Revolutionary cOFM-based approach providing direct access to functional tumor tissue without trauma generation, ensuring reliable and physiologically relevant data collection.
  • Orthotopic Xenograft Development: Precise implantation of tumor cells into brain tissue with intact blood-brain barrier, creating clinically relevant tumor models that develop naturally at the probe-tissue interface.
  • High Success Rate Models: Proven methodology achieving consistently high tumor development success rates (>70%), ensuring efficient study execution and reliable experimental outcomes.
  • Intact Microenvironment Preservation: Maintenance of physiological tumor microenvironment conditions, allowing for accurate assessment of drug penetration, efficacy, and biomarker expression in realistic tissue conditions.
  • Real-Time Tumor Monitoring: Continuous sampling of interstitial fluid from functional tumor tissue in vivo, enabling dynamic assessment of therapeutic responses and biomarker changes over time.
  • Comparative Model Validation: Comprehensive characterization of cOFM-induced tumors alongside traditional injection methods, ensuring model validity and translational relevance for human applications.
  • BBB-Intact Tumor Studies: Investigation of blood-brain barrier function within intact tumor tissue, providing critical insights for CNS drug development and understanding of tumor-BBB interactions.

Our advanced methodology delivers unprecedented access to functional tumor tissue while preserving physiological conditions, enabling reliable data generation for drug research, biomarker identification, and therapeutic development in oncology.

openflowmicroperfusion.com

More information

To learn more about our innovative technology and its application, please visit our dedicated OFM website.

Contact Us

 

Learn more about our Preclinical Study Sercices

Schedule a conversation with
our experts: croservices@joanneum.at